Lineage Cell Therapeutics Continues Support for Roche/Genentech’s OpRegen Cell Therapy, AlloSCOPE™ Platform Enables Scalable Manufacturing

August 9, 2026

Business Wire USA

Overview

Lineage Cell Therapeutics reported Q2 2026 financial results and business updates, confirming continued support for its OpRegen cell therapy development collaboration with Roche and Genentech, including technical training and material provision for commercial manufacturing strategies. Lineage’s proprietary AlloSCOPE™ platform enables consistent, cost-effective, and scalable production of millions of doses of allogeneic cell-based products from a single pluripotent cell line. This accelerates market entry for regenerative medicine products and aims to make them accessible to more patients.

In Depth

Key Findings

Lineage Cell Therapeutics released its second-quarter 2026 financial results and provided a business update, announcing its continued support for the OpRegen cell therapy development collaboration with pharmaceutical giants Roche and Genentech. This support encompasses technical training and the provision of materials essential for the commercial manufacturing strategy of OpRegen.

Technical / Clinical Details

OpRegen is a retinal pigment epithelial (RPE) cell replacement therapy designed to treat age-related macular degeneration (AMD). Lineage contributes its specialized expertise and technology for generating RPE cells, while Roche/Genentech lead the subsequent clinical development and commercialization. This collaboration exemplifies a typical partnership between a major pharmaceutical company and a biotechnology firm in the regenerative medicine sector, aiming to accelerate the development and market introduction of complex cell therapy products.

The core technology of Lineage Cell Therapeutics, the AlloSCOPE™ platform, demonstrates its strength in the manufacturing of allogeneic (off-the-shelf) cell-based products. This platform enables the consistent, cost-effective, and scalable production of millions of doses of cell-based products from a single pluripotent cell line (e.g., iPSC). Traditional autologous cell therapies often face high manufacturing costs and scalability limitations due to the need for patient-specific cell collection and processing. Platforms like AlloSCOPE™ overcome these challenges, facilitating the production of ‘off-the-shelf’ products that can make cell therapies accessible to a larger patient population.

This technology is expected to lead to standardization of manufacturing processes, enhanced quality control, and reduced production costs. Furthermore, providing technical training and materials to Roche/Genentech is a critical component for smooth transition towards commercial-scale manufacturing of OpRegen.

Background & Context

Age-related macular degeneration is a leading cause of irreversible blindness in developed countries, with limited effective treatments. The degeneration of RPE cells is central to the disease’s pathology, making RPE cell replacement therapy a promising approach for vision preservation or restoration. Across the regenerative medicine field, manufacturing scalability and cost-effectiveness remain major barriers to widespread adoption of therapies. Allogeneic platforms like AlloSCOPE™ are crucial for addressing these challenges and enhancing the commercial viability of cell therapies. The trend of major pharmaceutical companies actively investing in cell therapy and partnering with specialized firms reflects the growth and maturation of this sector.

Strategic Significance & Outlook

Lineage Cell Therapeutics’ continued support for Roche/Genentech and the utilization of the AlloSCOPE™ platform are indispensable for the successful commercialization of OpRegen. If successful, this collaboration could offer a breakthrough treatment option for AMD patients, potentially saving many from the threat of blindness. The capabilities of the AlloSCOPE™ platform are not limited to OpRegen but hold potential for the development and commercialization of many other allogeneic cell therapy products, playing a critical role in enhancing overall manufacturing efficiency and accessibility in the regenerative medicine sector. This strategy has the potential to become an industry-wide model for transitioning cell therapies from research to practical treatments.

Source: #

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.